Key Highlights

  • Beverage revenue was $667,942 in the quarter ended March 31, 2026, exceeding the $631,332 recorded for the full twelve months of fiscal 2025.
  • Total revenue fell to $5.49 million from $8.17 million a year earlier, and the company swung from net income of $876,264 to a net loss of $2,568,899.
  • Cash was $292,115 at March 31, 2026 against $27.75 million of net notes payable and a $25.4 million stockholders' deficit.
  • The amended credit agreement requires minimum consolidated adjusted EBITDA of $500,000 for the quarter ending June 30, 2026 and $1,000,000 for the quarter ending September 30, 2026, and imposes a 2.00% interest margin step-up from October 1, 2026 unless Synergy raises at least $10 million of net equity proceeds by September 30, 2026.

Why Synergy CHC Corp. Is Drawing Investor Attention

Synergy CHC Corp. (NASDAQ:SNYR) is a Nevada-incorporated consumer health company based in Maine with two brands of consequence: FOCUSfactor, a brain-health supplement bought in January 2015 for $6.0 million including earnout, and Flat Tummy, a women's wellness line acquired in November 2015 for about $7.0 million. Its shares trade on the Nasdaq Capital Market.

The attention is not coming from the supplement business, which shrank in the March quarter, but from the ready-to-drink line extension. Synergy has been pushing FOCUSfactor into functional beverages since 2023 with limited traction. In the first quarter of fiscal 2026 that changed abruptly - just as the company's leverage, cash position and listing compliance came under strain.

Inside the Business: What Synergy CHC Actually Does

Synergy is an asset-light brand owner: it designs and markets products, outsources manufacturing, and sells through large retail accounts and its own websites. The 2025 annual report identifies Costco, Amazon.com, Walmart, Walgreens, BJ's and The Vitamin Shoppe as principal customers, with Canada entered in 2020 and Mexico in late 2025.

FOCUSfactor carries more than 34 stock-keeping units and is the revenue engine. Flat Tummy, with 13 SKUs, is run as a social-first brand: roughly 1.7 million Instagram followers and about 1.9 million app downloads as of December 31, 2025, with protein shakes and GLP-1 support products added in early 2025.

Synergy splits revenue three ways - nutraceuticals, beverages and consumer goods - and separately by channel. In fiscal 2025 nutraceuticals produced $29.73 million of the $30.38 million total. That is the context for the beverage story: a small line inside a supplement company, not yet a second business.

The Beverage Inflection: What the Numbers Say About FOCUSfactor RTD

The headline claim checks out, and the basis matters. Synergy's segment disclosure shows beverage revenue of $667,942 for the three months ended March 31, 2026, against $30,970 a year earlier. The fiscal 2025 annual report shows $631,332 for the full twelve months. So a single quarter did surpass an entire prior year - by roughly 6%.

The comparison flatters the trend, because fiscal 2025 was a poor year for the category. Beverage revenue in fiscal 2024 was $1,425,239, so the line more than halved in 2025 before rebounding. Against the fiscal 2024 quarterly average of about $356,000, the March 2026 quarter is still up close to 90% - the more honest framing. This is growth off a reset base, not a straight-line breakout.

The strategic logic is sound. Synergy has developed FOCUSfactor focus-and-energy ready-to-drink products since a US retail pilot in 2023, followed by three RTD launches in Canada in the second quarter of 2024. Beverages reach consumption occasions a pill bottle cannot.

What remains unproven is durability and profitability. One quarter of $668,000 does not establish a repeat-purchase pattern, and beverage gross margin is not disclosed separately. Group gross margin fell to 72.3% from 75.4%, consistent with - though not proof of - a shift toward a lower-margin format. Nor has Synergy quantified the distribution behind the increase, or named a new beverage account. Until the line clears roughly $1 million in a quarter with disclosed margins, calling it a growth engine is a forecast rather than a finding.

Latest Financial and Operational Performance

Synergy reported the three months ended March 31, 2026 on May 14, 2026. Total revenue was $5,492,705 against $8,170,534 a year earlier. The comparison is distorted by $1.5 million of licence revenue in the 2025 quarter; on product sales alone, revenue fell from $6,670,534 to $5,492,705, a decline of 17.7%.

Nutraceuticals - FOCUSfactor supplements and Flat Tummy - dropped to $4,824,763 from $6,639,564. By channel, retail fell to $3,705,620 from $5,408,689 and online to $1,787,085 from $2,761,845. Gross profit was $3,970,795, a 72.3% margin.

Operating expenses rose to $4,537,915 from $4,216,318, with general and administrative costs up to $2,048,850 from $1,306,714 while selling and marketing was cut to $2,455,732. The result was an operating loss of $567,120, reversing operating income of $1,947,703. Interest expense of $2,012,121, nearly double the prior year, drove a net loss of $2,568,899, or $0.23 per share, against net income of $876,264 a year earlier.

Balance Sheet, Cash Position and Funding

The balance sheet is the central issue. At March 31, 2026 Synergy held $292,115 of cash plus $100,000 restricted. Total assets were $6,461,591 against liabilities of $31,866,841, producing a stockholders' deficit of $25,405,250 and an accumulated deficit of $59,009,920. The company disclosed a working capital deficit of $503,862 and operating cash outflow of $2,044,678.

Notes payable totalled $31,150,656 gross, or $27,749,036 net of unamortised discount. The senior facility is a term loan credit agreement dated May 30, 2025 with ACP Agency, LLC, secured on substantially all assets including a pledge of intellectual property; it carried $17,725,033 at an effective 14.25% and matures in May 2029. Behind it sit $9,595,223 of subordinated notes bearing 12% and a $4,032,000 receivables advance from Cedar Advance LLC, entered on March 10, 2026, that repays at $100,800 per week.

Notably, there is no Knight Therapeutics loan outstanding. Knight, which historically financed Synergy, now appears only as a shareholder and as counterparty to a 2016 royalty and distribution arrangement, with $196,934 owed at December 31, 2025.

Management concluded that its plans - the amended credit agreement, headcount reduction, equity issuance and an equity line of credit disclosed on May 11, 2026 - alleviate going-concern doubt. In April 2026 Synergy sold 3,278,030 shares under its at-the-market programme for $2,673,201 gross.

Growth Opportunities and Upcoming Milestones

Geographic expansion is the clearest lever. Mexico launched in the fourth quarter of 2025, Taiwan and wider Asia are planned for 2026 beginning with FOCUSfactor, and the company holds Therapeutic Goods Administration approval for FOCUSfactor in Australia, where the brand is not yet sold. Within existing accounts the strategy is SKU expansion, lifting points of distribution rather than winning new retailers.

The measurable near-term tests are set by the lenders. The amended credit agreement requires minimum consolidated adjusted EBITDA of $500,000 for the quarter ending June 30, 2026 and $1,000,000 for the quarter ending September 30, 2026, and imposes a 2.00% interest margin step-up from October 1, 2026 unless Synergy raises at least $10 million of net equity proceeds by September 30, 2026. Those two dates matter more to the equity than any product launch.

Material Risks Specific to Synergy CHC

Leverage against a shrinking top line is the dominant risk: interest expense of $2.01 million consumed more than half of gross profit. The receivables advances are especially costly - the March 2026 advance delivered $980,000 in net cash against a $4,032,000 repayment obligation.

Two lender disputes are live. ACP has informally alleged a default under the credit agreement, though no formal written notice has been received and the company says it does not believe it is in default. Separately, the holder of the subordinated notes asserted in March 2026 that the loan had matured and declined an extension, a position Synergy rejects because the debt is fully subordinated.

Dilution is accelerating: shares outstanding rose from 11,303,853 at March 31, 2026 to 14,899,883 by May 11, 2026, and the March amendment came with a warrant to Acme Credit Partners Fund I, LP over 3,000,000 shares at $0.00001.

Listing compliance is at risk: on May 15, 2026 Synergy received notice that it no longer met the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), with an initial compliance period to November 11, 2026. Concentration among a handful of large retailers compounds the rest.

A Balanced Outlook: Upside, Base Case and Downside

Upside. Beverage revenue holds above the March-quarter run rate, the Asian launches contribute in the second half, the EBITDA covenants are met, and Synergy raises the $10 million of equity that avoids the margin step-up. Deleveraging then becomes possible.

Base case. The beverage line grows but stays a modest share of revenue while nutraceutical sales remain soft. Covenants are met narrowly, financing continues through the equity line and receivables advances, and dilution remains the price of liquidity.

Downside. Supplement sales keep declining, the June or September EBITDA thresholds are missed, the informal default allegation becomes formal, and the lender warrant becomes exercisable - leaving the November listing deadline to arrive with the balance sheet weaker than today.

Conclusion

The beverage claim about Synergy CHC Corp. (SNYR) is accurate and worth knowing: $667,942 in one quarter against $631,332 in the prior full year is a genuine change in trajectory for FOCUSfactor's ready-to-drink line. But it is a small line growing off a halved base, inside a company whose product sales fell 18%, whose interest bill consumed half of gross profit, and which held under $300,000 of cash against nearly $28 million of net debt. FOCUSfactor RTD may yet become a growth engine; on the March quarter's evidence it is not yet one.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.